Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/09/697
Active ingredient: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
Indication: Treatment of naevoid basal cell carcinoma syndrome (Gorlin syndrome)
Sponsor: Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

   Public summary of scientific opinion    


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
27/11/2009 Centralised Orphan - Designation EMEA/OD/048/09 (2009)9499 of 25/11/2009
15/01/2013 Centralised Orphan - Removal of orphan designation from Community Register